PURE

PURE BIOSCIENCE, INC.
CAPPED RATING

PURE Bioscience, Inc. engages in the discovery, development, and commercialization of proprietary antimicrobial products for pathogen and hygienic control. It offers silver dihydrogen citrate-based disinfecting and sanitizing products. The company was founded by Michael L. Krall on August 24, 1992 and is headquartered in El Cajon, CA.

PURE BIOSCIENCE, INC. (PURE) is rated C+ (2.5/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (A+); its weakest is Profitability (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C+
Value
C+
Factor Score 2.8 / 5.0
Growth
A+
Factor Score 4.9 / 5.0
Profitability
D-
Factor Score 1.1 / 5.0
Momentum
C
Factor Score 2.5 / 5.0
Revisions
D
Factor Score 1.3 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 46.1%
Gross Margin 53.3%
Price Return 3M -0.1%
Price Return 12M -0.1%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 13.0
ROE -379.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2023-07-31 C+ (2.8) A+ (4.9) D- (1.1) C (2.5) D (1.3) C+ (2.5)
2023-04-30 C+ (2.7) F (0.3) D (1.3) C (2.5) C+ (2.5) C- (1.9)
2023-01-31 C+ (2.7) D (1.3) D- (0.9) C (2.5) C+ (2.5) C- (2.0)
2022-10-31 C+ (2.8) D (1.2) D+ (1.6) C (2.5) C+ (2.5) C- (2.1)
2022-07-31 C+ (2.8) F (0.0) D- (1.1) C (2.5) D (1.4) D+ (1.6)
Page 1 of 3